Across TCGA pan-cancer cohorts, RPL23AP53 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPL23AP53 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RPL23AP53 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPL23AP53 expression acts as an unfavorable survival marker.

LUSC and CESC are the cancer types where RPL23AP53 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.168	0.659	.027	12	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPL23AP53 tumor-vs-normal RNA expression · all RPL23AP53 data types